In addition, selpercatinib had superior therapeutic effects versus other multikinase inhibitors (cabozantinib and vandetanib) in patients with RET mutation-positive MTC as shown in the LIBRETTO-531 trial, a multicenter, nonblinded, randomized phase III trial [16]. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.